Glucositin

Glucositin is an oral tablet that contains the active ingredient sitagliptin, a dipeptidyl peptidase‑4 (DPP‑4) inhibitor approved in the European Union for the treatment of type 2 diabetes mellitus. It is a prescription‑only medication that works by enhancing the body’s natural incretin response to improve blood glucose control.

Glucositin is prescribed as part of a comprehensive diabetes management plan that includes diet, exercise, and other glucose‑lowering agents when needed.

- Monotherapy for type 2 diabetes in patients who cannot tolerate metformin. - Combination therapy with metformin when glycemic control is inadequate. - Adjunct to lifestyle modifications to reduce post‑prandial glucose spikes. - Use in adults with established type 2 diabetes mellitus. - May be considered when renal function is stable and within prescribing limits.

Side effects of Glucositin vary in frequency and severity. Patients should be aware of both common and potentially serious reactions.

Common: - Upper respiratory tract infection - Headache - Nasopharyngitis - Nausea - Diarrhea

Serious: - Pancreatitis (severe abdominal pain) - Severe allergic reactions such as angioedema - Hypersensitivity skin reactions (e.g., Stevens‑Johnson syndrome) - Acute renal failure in susceptible individuals

Before starting Glucositin, clinicians should evaluate several safety considerations.

- Assess renal function; dose adjustment may be required in impaired kidneys. - Review patient history for pancreatitis or pancreatic disease. - Monitor for signs of hypersensitivity, especially skin eruptions. - Use caution in patients with a history of heart failure. - Evaluate liver function periodically, although significant hepatic effects are rare. - Discuss pregnancy and breastfeeding status, as safety data are limited.

Glucositin can interact with other medicines, influencing its efficacy or safety.

Avoid: - Strong CYP3A4/5 inhibitors (e.g., ketoconazole, clarithromycin) that may increase sitagliptin exposure. - Concurrent use with other DPP‑4 inhibitors or GLP‑1 receptor agonists without medical supervision.

Use with caution: - Diuretics, especially thiazides, due to potential effects on blood glucose. - Insulin or sulfonylureas, as additive hypoglycemia risk may occur. - Rifampin, which can reduce sitagliptin plasma concentrations. - NSAIDs, which may affect renal function when combined with sitagliptin.